相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Age-dependent decline of neprilysin in Alzheimer's disease and normal brain:: Inverse correlation with Aβ levels
E. Hellstrom-Lindahl et al.
NEUROBIOLOGY OF AGING (2008)
Differential modulation of Alzheimer's disease amyloid β-peptide accumulation by diverse classes of metal ligands
Aphrodite Caragounis et al.
BIOCHEMICAL JOURNAL (2007)
Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2007)
Amyloid-β in Alzheimer disease:: The null versus the alternate hypotheses
Hyoung-gon Lee et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
Howard H. Feldman et al.
LANCET NEUROLOGY (2007)
Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease
Rashid Deane et al.
CURRENT ALZHEIMER RESEARCH (2007)
Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?
Patrick G. Kehoe et al.
LANCET NEUROLOGY (2007)
Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease
Matthew L. Hemming et al.
NEUROBIOLOGY OF DISEASE (2007)
Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid
D. M. Wilcock et al.
NEUROSCIENCE (2007)
Interferon-γ and tumor necrosis factor-a regulate amyloid-α plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice
Masaru Yamamoto et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain A beta levels
Idan Rakover et al.
NEURODEGENERATIVE DISEASES (2007)
Disease-modifying trials in Alzheimer's disease: a European task force consensus
Bruno Vellas et al.
LANCET NEUROLOGY (2007)
A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
P. S. Aisen et al.
NEUROLOGY (2006)
Regulation of steady-state β-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme
Elizabeth A. Eckman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease:: OmegAD study -: A randomized double-blind trial
Yvonne Freund-Levi et al.
ARCHIVES OF NEUROLOGY (2006)
RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease
John E. Donahue et al.
ACTA NEUROPATHOLOGICA (2006)
Rationale for combination therapy with galantamine and Memantine in Alzheimer's disease
George T. Grossberg et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
What constitutes clinical evidence for neuroprotection in Alzheimer disease - Support for the cholinesterase inhibitors?
E Mori et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2006)
Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease
ER Siemers et al.
NEUROLOGY (2006)
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
RM Lane et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2006)
Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ
M Sastre et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Cholinesterase inhibitors for Alzheimer's disease
J Birks
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
alpha-secretase activation - An approach to Alzheimer's disease therapy
Falk Fahrenholz et al.
NEURODEGENERATIVE DISEASES (2006)
Global prevalence of dementia: a Delphi consensus study
CP Ferri et al.
LANCET (2005)
Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor
ML Hemming et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone - A preliminary study
GS Watson et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2005)
Effect of baseline cognitive function and anti hypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE)
I Skoog et al.
AMERICAN JOURNAL OF HYPERTENSION (2005)
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
NC Fox et al.
NEUROLOGY (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation
T Saito et al.
NATURE MEDICINE (2005)
A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model
GP Lim et al.
JOURNAL OF NEUROSCIENCE (2005)
The K variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients
C Ballard et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2005)
Dietary intake of fatty acids and fish in relation to cognitive performance at middle age
[Anonymous]
NEUROLOGY (2004)
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial
PN Tariot et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease
RC Dodel et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Metal and inflammatory targets for Alzheimer's disease
JT Rogers et al.
CURRENT DRUG TARGETS (2004)
RAGE (Yin) versus LRP (Yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier
R Deane et al.
STROKE (2004)
Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis
A Dedeoglu et al.
EXPERIMENTAL GERONTOLOGY (2004)
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
R Deane et al.
NATURE MEDICINE (2003)
Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimer's disease
C Hock et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2003)
Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease - A meta-analysis
NH Trinh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A beta amyloid deposition and toxicity in Alzheimer disease - A pilot phase 2 clinical trial
CW Ritchie et al.
ARCHIVES OF NEUROLOGY (2003)
M-1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease - Implications in future therapy
A Fisher et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2003)
Cerebral hemorrhage after passive anti-Aβ immunotherapy
M Pfeifer et al.
SCIENCE (2002)
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
S Weggen et al.
NATURE (2001)
Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation
Y Luo et al.
NATURE NEUROSCIENCE (2001)
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease - A randomized controlled trial
RI Mulnard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
